Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...
has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara® 1), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA 2 goal date ...
The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related ...
Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...
The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...
must submit an NDS within 12 months of filing a New Drug Application (NDA) in the US. This requirement is established by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback